Based on previous reports, CD19-target CAR T-cell salvage was shown to have very high response rates in the relapsed/refractory B-ALL setting (6, 7); thus, CAR T-cell salvage should be a better option than in-class switch of TKI. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.